Clearside BiomedicalCLSDQ 49 Net Margin % is -2,971.14% as of Sep. 2025. GuruFocus rates CLSDQ with a GF Score™ of 49/100 and a GF Value™ of $6.34 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 938 Biotechnology companies, Clearside Biomedical ranks worse than 75.91% on this metric.
The historical rank and industry rank for Clearside Biomedical's Net Margin % or its related term are showing as below:
CLSDQ'
s Net Margin % Range Over the Past 10 Years
Min: -276060 Med: -2064.42 Max: 1.27
Current: -780.9
CLSDQ's Net Margin % is ranked worse than 75.91% of 938
companies
in the Biotechnology industry
Industry Median: -88.295
vs CLSDQ: -780.90
Clearside Biomedical (OTCPK:CLSDQ) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Clearside Biomedical Net Margin % Related Terms
Clearside Biomedical Net Margin % Historical Data
* Premium members only.
The historical data trend for Clearside Biomedical's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLSDQ vs LYRA, EVFM, ATXI: Net Margin % Comparison
For the Biotechnology subindustry, Clearside Biomedical's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearside Biomedical Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Clearside Biomedical's Net Margin % distribution charts can be found below:
* The bar in red indicates where Clearside Biomedical's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clearside Biomedical (CLSDQ) has a Net Margin % of -2,971.14% as of Sep. 2025. Net margin is the ratio of total net income to net sales. View historical data on Clearside Biomedical and its competitors. According to the industry distribution chart, Clearside Biomedical ranks #712 out of 938 companies in the Biotechnology industry, placing it in the top 75.9%.
Is Clearside Biomedical's Net Margin % too high?
Clearside Biomedical's current Net Margin % is -2,971.14%. Based on the distribution chart, Clearside Biomedical ranks #712 out of 938 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Clearside Biomedical has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clearside Biomedical's Net Margin % compare to LYRA and EVFM?
According to the Biotechnology industry distribution chart, Clearside Biomedical ranks #712 out of 938 companies for Net Margin %. This places Clearside Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Clearside Biomedical and its competitors. Clearside Biomedical's current Net Margin % is -2,971.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearside Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Clearside Biomedical (CLSDQ) is currently considered Possible Value Trap. The stock's GF Value™ is $6.34, compared to a current price of $0.13 — trading 98% below its estimated fair value. The current Net Margin % is -2,971.14%. Clearside Biomedical's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Clearside Biomedical (CLSDQ), the current Net Margin % is -2,971.14% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clearside Biomedical (CLSDQ) Overvalued in 2026?
Based on GuruFocus' analysis, Clearside Biomedical stock appears to be undervalued.
The current stock price of $0.13 is trading 98% below its estimated GF Value™ of $6.34.
GuruFocus considers Clearside Biomedical to be Possible Value Trap.
Key valuation signals for CLSDQ:
Net Margin %: -2,971.14%
GF Value™: $6.34 vs. price of $0.13 (98% below fair value)
No single metric tells the full story. See the CLSDQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.
49GF Score
Get the complete analysis for CLSDQ
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLSDQ has been successfully added to your 
